Completed PHASE2 NCT00035555

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Phase II/III, Open-Label, Randomized, Controlled, Multiple-Dose Study of Efficacy and Safety of BMS-224818 (Belatacept) as Part of a Quadruple Drug Regimen in First Renal Transplant Recipients

Sponsor: Bristol-Myers Squibb

Conditions Graft Rejection Kidney Transplantation Renal Transplantation

Interventions Belatacept Corticosteroids Cyclosporine Mycophenolate mofetil (MMF)

Updated 6 times since 2017 Last updated: Nov 27, 2013 Started: Mar 31, 2001 Primary completion: Jan 31, 2004 Completion: Jul 31, 2012

Listed as NCT00035555, this PHASE2 trial focuses on Graft Rejection and Kidney Transplantation and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Boston, United States , Charleston, United States , Dallas, United States , Livingston, United States , Madison, United States , New York, United States , Omaha, United States , Philadelphia, United States and 2 more locations